Belpointe Asset Management LLC Grows Stake in Boston Scientific Corporation $BSX

Key Points

• Belpointe Asset Management LLC increased its stake in Boston Scientific Corporation by 119.4% in Q2, owning 5,048 shares valued at approximately $542,000.
• Boston Scientific reported $5.06 billion in revenue for the last quarter, exceeding expectations and marking a 22.8% increase year-over-year.
• Equity analysts have set price targets for Boston Scientific shares ranging from $121.00 to $136.00, maintaining a consensus rating of "Buy."

Belpointe Asset Management LLC raised its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 119.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,048 shares of the medical equipment provider's stock after acquiring an additional 2,747 shares during the period. Belpointe Asset Management LLC's holdings in Boston Scientific were worth $542,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of BSX. Vanguard Group Inc. raised its position in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Swedbank AB raised its position in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock valued at $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd raised its position in Boston Scientific by 33.5% during the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider's stock valued at $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.5%

Boston Scientific stock opened at $97.28 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The business's 50-day simple moving average is $102.18 and its two-hundred day simple moving average is $101.92. The company has a market cap of $144.14 billion, a PE ratio of 57.91, a PEG ratio of 2.33 and a beta of 0.61. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the business earned $0.62 EPS. The company's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BSX shares. Canaccord Genuity Group lifted their target price on Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a research report on Wednesday, October 1st. Raymond James Financial lifted their target price on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Weiss Ratings reissued a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Wednesday, October 1st. Finally, Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $120.71.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.